Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionQSML - WisdomTree U.S. SmallCap Quality Growth Fund
Latest Disclosed Ownership1,379 shares
Latest Disclosed Value $ 34,144
QSML - WisdomTree U.S. SmallCap Quality Growth Fund ownership in CPRX / Catalyst Pharmaceuticals, Inc.

On June 1, 2026 - QSML - WisdomTree U.S. SmallCap Quality Growth Fund filed a NPORT-P form disclosing ownership of 1,379 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $34,144 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 27, 2026 disclosing 1,379 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $43,425 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-06-01 2026-03-31 NP Catalyst Pharmaceuticals Inc. COM EC US14888U1016 1,379 0 0.00 34 6.25 0.3497
2026-02-27 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,379 82 6.32 32 28.00 0.3196
2025-11-25 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,297 26 2.05 26 -7.41 0.2779
2025-08-29 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,271 -32 -2.46 28 -12.90 0.3226
2025-05-30 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,303 136 11.65 32 29.17 0.4319
2025-02-28 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,167 132 12.75 24 20.00 0.3231
2024-11-27 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,035 350 51.09 21 100.00 0.3373
2024-08-28 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 685 469 217.13 11 233.33 0.2819
2024-05-21 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 216 216 3 0.2624
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.